Phase Ⅲ Randomized Trial in Postoperative Hepatocellular Carcinoma

NCT00149565 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

268

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

DRUG: IFN-α2b

Sponsor

National Health Research Institutes, Taiwan

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]